Spooner Kimberly, Fraser-Bell Samantha, Hong Thomas, Chang Andrew A
Research, Sydney Institute of Vision Science, Sydney, New South Wales, Australia.
Department of Ophthalmology, University of Sydney, Sydney, New South Wales, Australia.
BMJ Open Ophthalmol. 2019 Mar 29;4(1):e000249. doi: 10.1136/bmjophth-2018-000249. eCollection 2019.
Report 5-year outcomes of patients receiving anti-vascular endothelial growth factor (VEGF) for the treatment of macular oedema secondary to retinal vein occlusion (RVO.
Retrospective review of eyes with RVO which initiated anti-VEGF treatment. Data including age, gender, visual acuity (VA) and injection numbers were obtained from medical records. Optical coherence tomography scans were graded for presence or absence of macular oedema and central foveal thickness (CFT). Macular perfusion was assessed on fundus fluorescein angiography by masked graders.
68 eyes (31 branch RVO, BRVO; 35 central RVO, CRVO and 2 hemi-RVO) with 5 years of follow-up after initiation of anti-VEGF treatment. Mean change in VA at 5 years was + 9.6 ± 21.6 letters among CRVO eyes and + 14.2 ± 15.6 letters among eyes with BRVO (p=0.001). Vision of 20/40 or better was achieved in 65 % of treated eyes. The proportion of eyes with a three-line improvement of vision (15 letters) at 5 years was 22 %. Mean CFT decreased by 257.6 ± 249.8 µm in eyes with CRVO and 145.6 ± 143.3 µm in eyes with BRVO.
The results confirm good long-term outcomes can be achieved with anti-VEGF therapy for RVO.
报告接受抗血管内皮生长因子（VEGF）治疗视网膜静脉阻塞（RVO）继发黄斑水肿患者的5年治疗结果。
对开始抗VEGF治疗的RVO患眼进行回顾性研究。从病历中获取包括年龄、性别、视力（VA）和注射次数等数据。光学相干断层扫描根据有无黄斑水肿和中心凹厚度（CFT）进行分级。由经验丰富的医生通过眼底荧光血管造影评估黄斑灌注情况。
68只患眼（31只分支RVO，BRVO；35只中央RVO，CRVO和2只半侧RVO）在开始抗VEGF治疗后进行了5年随访。CRVO患眼中5年时VA的平均变化为+9.6±21.6字母，BRVO患眼中为+14.2±15.6字母（p = 0.001）。65%的治疗患眼视力达到20/40或更好。5年时视力提高3行（15个字母）的患眼比例为22%。CRVO患眼中平均CFT下降257.6±249.8 µm，BRVO患眼中下降145.6±143.3 µm。
结果证实抗VEGF治疗RVO可取得良好的长期治疗效果。
